104 related articles for article (PubMed ID: 8453624)
1. Protective effects of recombinant human interleukin-1 alpha in doxorubicin-treated normal and tumor-bearing mice.
Lynch DH; Rubin AS; Miller RE; Williams DE
Cancer Res; 1993 Apr; 53(7):1565-70. PubMed ID: 8453624
[TBL] [Abstract][Full Text] [Related]
2. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
[TBL] [Abstract][Full Text] [Related]
3. Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities.
Damia G; Komschlies KL; Futami H; Back T; Gruys ME; Longo DL; Keller JR; Ruscetti FW; Wiltrout RH
Cancer Res; 1992 Aug; 52(15):4082-9. PubMed ID: 1638519
[TBL] [Abstract][Full Text] [Related]
4. [Application of interleukin 1 in the treatment of malignant gliomas with special reference to the experimental combination therapy with ACNU].
Tanaka S
Gan To Kagaku Ryoho; 1990 Jun; 17(6):1157-64. PubMed ID: 2350191
[TBL] [Abstract][Full Text] [Related]
5. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
6. Effects of interleukin 2 treatment combined with local hyperthermia in mice inoculated with Lewis lung carcinoma cells.
Shen RN; Lu L; Wu B; Shidnia H; Hornback NB; Broxmeyer HE
Cancer Res; 1990 Aug; 50(16):5027-30. PubMed ID: 2379168
[TBL] [Abstract][Full Text] [Related]
7. Contrasting mechanisms of the myeloprotective effects of interleukin-1 against ionizing radiation and cytotoxic 5-fluorouracil.
Neta R; Keller JR; Ali N; Blanchette F; Dubois CM
Radiat Res; 1996 May; 145(5):624-31. PubMed ID: 8619029
[TBL] [Abstract][Full Text] [Related]
8. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
9. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
10. The role of recombinant interleukin 11 in megakaryocytopoiesis.
Turner KJ; Neben S; Weich N; Schaub RG; Goldman SJ
Stem Cells; 1996; 14 Suppl 1():53-61. PubMed ID: 11012203
[TBL] [Abstract][Full Text] [Related]
11. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.
Kawano H; Komaba S; Yamasaki T; Maeda M; Kimura Y; Maeda A; Kaneda Y
Cancer Chemother Pharmacol; 2008 May; 61(6):973-8. PubMed ID: 17653716
[TBL] [Abstract][Full Text] [Related]
12. Prevention of doxorubicin-induced hematotoxicity in mice by interleukin 1.
Eppstein DA; Kurahara CG; Bruno NA; Terrell TG
Cancer Res; 1989 Jul; 49(14):3955-60. PubMed ID: 2786748
[TBL] [Abstract][Full Text] [Related]
13. Prevention of fatal infections by recombinant human interleukin 1 alpha in normal and anticancer drug-treated mice.
Morikage T; Mizushima Y; Sakamoto K; Yano S
Cancer Res; 1990 Apr; 50(7):2099-104. PubMed ID: 2317799
[TBL] [Abstract][Full Text] [Related]
14. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
15. Sinusoidal endothelium release of hydrogen peroxide enhances very late antigen-4-mediated melanoma cell adherence and tumor cytotoxicity during interleukin-1 promotion of hepatic melanoma metastasis in mice.
Anasagasti MJ; Alvarez A; Martin JJ; Mendoza L; Vidal-Vanaclocha F
Hepatology; 1997 Apr; 25(4):840-6. PubMed ID: 9096586
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 1 alpha (IL-1) and macrophage colony-stimulating factor (M-CSF) accelerate recovery from multiple drug-induced myelosuppression.
Kovacs CJ; Kerr JA; Daly BM; Evans MJ; Johnke RM
Anticancer Res; 1998; 18(3A):1805-12. PubMed ID: 9673408
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 1 alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells.
Chang MJ; Modzelewski RA; Russell DM; Johnson CS
Cancer Res; 1996 Feb; 56(4):886-91. PubMed ID: 8631029
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors.
Braunschweiger PG; Basrur VS; Santos O; Markoe AM; Houdek PV; Schwade JG
Cancer Res; 1993 Mar; 53(5):1091-7. PubMed ID: 8439953
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant enzyme activity in murine hematopoietic bone marrow following treatment with interleukin 1 alpha: influence of tumor.
Johnke RM; Abernathy RS; Kovacs CJ; Evans MJ; Biggs LE; Daly BM; Loven DP
Anticancer Res; 1997; 17(3C):2169-74. PubMed ID: 9216682
[TBL] [Abstract][Full Text] [Related]
20. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat.
van Hoesel QG; Steerenberg PA; Crommelin DJ; van Dijk A; van Oort W; Klein S; Douze JM; de Wildt DJ; Hillen FC
Cancer Res; 1984 Sep; 44(9):3698-705. PubMed ID: 6744286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
